Novo Nordisk Offers Wegovy for $499 a Month

Direct-to-Consumer Program Launched for Obesity Drug Wegovy

Novo Nordisk has launched a direct-to-consumer program called NovoCare, which offers patients a reduced price for the obesity drug Wegovy. The program aims to provide access to Wegovy for individuals who are uninsured or insured on commercial plans that do not cover the cost of the medication.

How it Works

Through the NovoCare program, patients can purchase a month’s supply of Wegovy for $499, regardless of the dose strength, which is a significant reduction from the list price of $1,350 per month. The program is designed to lower costs for individuals whose insurance plans do not cover the cost of obesity medications. However, those on Medicare or Medicaid are ineligible for the program.

Key Features

• Patients can purchase a month’s supply of Wegovy for $499
• All dose strengths are priced the same
• Program is designed for individuals who are uninsured or insured on commercial plans that do not cover the cost of Wegovy
• NovoCare offers home deliveries and refill reminders for Wegovy prescriptions

Background

The Food and Drug Administration (FDA) removed Wegovy from the drug shortage list in late February, which means that compounding pharmacies can now legally create off-brand versions of the drug. However, insurance does not cover the cost of compounded drugs because they are not approved by the FDA.

Risks of Compounded Drugs

Novo Nordisk emphasizes that patients should avoid the risks associated with compounded drugs, which may not meet FDA standards for safety, effectiveness, and quality. The company notes that its FDA-approved Wegovy has undergone rigorous review, providing patients with clarity and confidence in its use.

Comparison to Telehealth Services

Telehealth companies, such as Hims & Hers and Ro, have emerged to offer lower-cost, off-brand obesity medications. However, some of these companies and unregulated pharmacies have sold versions of these drugs that are not FDA-approved or state-regulated. In contrast, NovoCare offers patients access to authentic, FDA-approved Wegovy.

Conclusion

The NovoCare program provides a new option for individuals who are uninsured or underinsured and are in need of Wegovy. By offering a reduced price and convenient access to the medication, NovoCare aims to make it easier for patients to manage their weight and achieve a healthier lifestyle.

FAQs

• What is the cost of Wegovy through NovoCare?
  • The cost of Wegovy through NovoCare is $499 per month.
• Who is eligible for the NovoCare program?
  • Patients who are uninsured or insured on commercial plans that do not cover the cost of Wegovy are eligible for the program.
• What is not covered by the NovoCare program?
  • Patients on Medicare or Medicaid are not eligible for the program.
• What services does NovoCare offer?
  • NovoCare offers home deliveries and refill reminders for Wegovy prescriptions.